Target Information

Target General Infomation
Target ID
T53472
Former ID
TTDI02107
Target Name
Killer cell immunoglobulin-like receptor 2DL3
Gene Name
KIR2DL3
Synonyms
CD158 antigenlike family member B2; CD158b2; KIR023GB; Killer inhibitory receptor cl 23; MHC class I NK cell receptor; NKAT2; NKAT2a; NKAT2b; Natural killerassociated transcript 2; p58 NK receptor CL6; p58 natural killer cell receptor clone CL6; p58.2 MHC classIspecific NK receptor; KIR2DL3
Target Type
Clinical Trial
Disease Acute myeloid leukemia [ICD9: 205; ICD10: C92.0]
Multiple myeloma [ICD9: 203; ICD10: C90]
Function
Receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). Inhibits the activity of NK cells thus preventing cell lysis.
BioChemical Class
Immunoglobulin
UniProt ID
P43628
Sequence
MSLMVVSMVCVGFFLLQGAWPHEGVHRKPSLLAHPGPLVKSEETVILQCWSDVRFQHFLL
HREGKFKDTLHLIGEHHDGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDI
VITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSREGEAHERRFSAGPKVNGT
FQADFPLGPATHGGTYRCFGSFRDSPYEWSNSSDPLLVSVTGNPSNSWPSPTEPSSETGN
PRHLHVLIGTSVVIILFILLLFFLLHRWCCNKKNAVVMDQEPAGNRTVNREDSDEQDPQE
VTYAQLNHCVFTQRKITRPSQRPKTPPTDIIVYTELPNAEP
Drugs and Mode of Action
Drug(s) IPH-2102 Drug Info Phase 2 Acute myeloid leukemia [524057]
mab 1-7F9 Drug Info Phase 2 Multiple myeloma [530228], [530238]
Antagonist IPH-2102 Drug Info [533076]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Antigen processing and presentation
Natural killer cell mediated cytotoxicity
Graft-versus-host disease
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
WikiPathways Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 524057ClinicalTrials.gov (NCT01687387) Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR). U.S. National Institutes of Health.
Ref 530228Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009 Sep 24;114(13):2667-77.
Ref 530238Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
Ref 530228Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009 Sep 24;114(13):2667-77.
Ref 530238Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
Ref 533076Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
Ref 544101Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009 September 24; 114(13): 2667-2677.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.